Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

The Guardian - UK

Eli Lilly calls UK ‘worst country in Europe’ for drug prices; gold nears record high - as it happened

Eli Lilly calls UK ‘worst country in Europe’ for drug prices; gold nears record high - as it happened

Spot gold trading just below Monday’s fresh record high

The Guardian - UK

Wegovy in pill form could soon be a reality as tests show it is just as effective as shots

Wegovy in pill form could soon be a reality as tests show it is just as effective as shots

It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred dollars each month out of pocket

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Novo Nordisk shares climb after positive anti-obesity pill results

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy

The Guardian - UK

New type of jab helps to maintain weight loss

Experts have developed a new drug which helps tackle the underlying causes of obesity.

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years

GSK plc (NYSE:GSK) on Wednesday announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?

Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a weight-related medical problem, and without diabetes.

This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

NHS staffer now forced to work extra shifts to cover cost of Mounjaro

NHS staffer now forced to work extra shifts to cover cost of Mounjaro

Carly Stokes, who has dropped 6st in a year using the weight-loss jab, will now have to pay £319 a month

The Independent UK

Vital breakthrough as once-a-day pill can help people lose ‘significant’ weight

Vital breakthrough as once-a-day pill can help people lose ‘significant’ weight

A fifth of people taking the weight-loss tablet Orforglipron lost 20 per cent of their body weight

The Independent UK

Daily weight loss pill can help cut body weight by a fifth, trial shows

Daily weight loss pill can help cut body weight by a fifth, trial shows

One in five people who took orforglipron once a day for 72 weeks lost 20% or more of their weight, maker Eli Lilly says

The Guardian - UK

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro (tirzepatide), both produced by Eli Lilly And Co. (NYSE:LLY), is false or misleading.

Get all your
news in one place.

100’s of premium titles.
One news app.

Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing

Eli Lilly and Co. (NYSE:LLY) announced on Tuesday that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County.

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment

Novo Nordisk A/S (NYSE:NVO) reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli Lilly and Co. (NYSE:LLY).

The Guardian - UK

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

Pharma Giant Eli Lilly (LLY) Could Still Be a Screaming Deal—Here’s the Statistical Evidence

Although healthcare juggernaut Eli Lilly has struggled for momentum this year, the latest unusual options activity for LLY stock could point to potential upside.

Get all your
news in one place.

100’s of premium titles.
One news app.

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

The Independent UK

Urgent warning over illegal weight loss jabs ‘not approved for humans’ offered for sale on TikTok

Exclusive: TikTok sellers purporting to sell the ‘Triple G’ of weight loss jabs have had their accounts pulled after The Independent exposed them to the social media giant

Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case

A federal appeals court has upheld a $183.7 million judgment against Eli Lilly and Co. (NYSE:LLY), rejecting the drugmaker's attempt to overturn a whistleblower lawsuit that accused it of defrauding Medicaid.

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.

Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies

The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'

Novo Nordisk (NYSE:NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE:LLY).

The Guardian - UK

Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition

Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly

People

166,825 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Independent

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

340,623 stories

131,377 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play